BROADCASTS.com

Dr. Daniel Karlin, Chief Medical Officer at MindMed, is bringing an updated approach to developing an LSD-based drug to treat anxiety and depression. Instead of developing a psychiatric medicine to be taken every day, MindMed is changing the paradigm to a session-based therapy that uses psychedelic drugs and therapists to improve psychiatric health. As a trained psychiatrist, Dan works at the intersection of psychiatry and neuroscience with this psychedelic-assisted therapeutic approach to brain health. 

Dan elaborates, "For quite some time, I think it feels like psychiatry hasn't been meeting people there. Treatments have been more focused on symptomatic resolution and these sorts of things, and visits with psychiatrists can feel too short and it can be really hard to find and afford psychotherapy. I think that what people are responding to about LSD and other drugs like it and their therapeutic potential is the sense that they offer something more than what people are able to access today. That there's real hope that these are drugs that can help people get at the real reasons they feel the way they feel and come to understand themselves better and their role in the world."

"There's another school of thought that the mechanism of these drugs is largely neurobiological and that the perceptual experience may not even be necessary. Of course, anytime we start to do binaries in biology, we're probably wrong. And it's probably some of both. And we operate under that hypothesis too, that the mechanism by which these drugs cause a psychedelic experience is very well explicated. The mechanism by which they cause lasting change isn't."

@MindMedco #MNMD $MNMD #PsychedelicMedicines #PsychedelicTherapy #LSD #Psychedelics #MentalHealth #BrainHealth #PsychiatricHealth 

mindmed.co

Download the transcript here